Skip to content
ESE logo
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas

Authors

Gerald Raverot, Pia Burman, Ann McCormack, Anthony Heaney, Stephan Petersenn, Vera Popovic, Jacqueline Trouillas, Olaf M Dekkers, on behalf of The European Society of Endocrinology

Developed By:

The European Society of Endocrinology

Introduction

Pituitary tumours are common and easily treated by surgery or medical treatment in most cases. However, a small subset of pituitary tumours does not respond to standard medical treatment and presents with multiple local recurrences (aggressive pituitary tumours) and in rare occasion with metastases (pituitary carcinoma). The overall purpose of this guideline is to provide clinicians with practical guidance for identification and management of patients with aggressive pituitary tumours. It was prompted by the increasing use of temozolomide (TMZ) in aggressive pituitary tumours.

European Journal of Endocrinology, Volume 178, Issue 1, Jan 2018, Pages G1–G24

Read the full Guideline

Published
01/01/2018
Tags
Guidelines , ESE Guideline , Pituitary and Neuroendocrinology ,
Other Publications